Exact Sciences (EXAS)
(Delayed Data from NSDQ)
$62.07 USD
+1.53 (2.53%)
Updated May 3, 2024 04:00 PM ET
After-Market: $62.08 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Brokerage Reports
0 items in cart
Exact Sciences Corporation [EXAS]
Reports for Purchase
Showing records 161 - 180 ( 364 total )
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
1Q15 Volume Outlook Light Despite Positive Early Metrics
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
4Q14 Preview - Expecting Healthy Test Ramp - Refining Our Street-High Model Lower for Medicare Advantage, Timing and Precedents - Maintain NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Updating Model - Early Commercial Traction Positive
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Healthcare: 4Q 2014: Quarterly Medical Technology Trading - Acquisition Valuation Update
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Preannouncement Watch - Look for Med Tech News into Next Weeks JPM Conference.
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
3Q14 Recap - Still Early for Sales, But Initial Dr. Sign-ups & Post CMS Order Acceleration Seems Good - Test Compliance Unknown - Maintain N
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 27
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
3Q14 Preview - Early Days for Revenue Collection - Volume Ramp, In-Network Contracting & Opex in Focus - Reaffirm N
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
3Q 2014: Quarterly Medical Technology Trading & Acquisition Valuation Update
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Upping PT to $19 from $14 Post Prelim CMS Pricing Decision
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
CMS Reimbursement Likely at $502 -Significant Win; Buy
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Receives Positive Recommendation for a National Coverage Decision from CMS
Provider: The Benchmark Company
Analyst: WALD J
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Wins FDA Approval; CMS Preliminary National Coverage Decision Process also Begins
Provider: The Benchmark Company
Analyst: WALD J